Key facts
- Cellular Intelligence’s last known valuation is $165.0M (Aug 2025).
- It has raised $70.3M; the latest was Early Stage VC ($60.0M) in Aug 2025.
- Notable investors include Khosla Ventures, Samsung NEXT Ventures, Harvard Innovation Launch Lab, Lerer Hippeau, Dhuna Ventures — 30 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Cellular Intelligence
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellular Intelligence are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellular Intelligence
Developer of a biotechnology platform designed to transform medical treatments, diseases, and therapeutic research approaches. The company's platform utilizes artificial intelligence to integrate and analyze vast amounts of biological, genetic, and clinical data to uncover insights into diseases, cell functions, and treatment responses, enabling research and pharmaceutical companies to accelerate the development and optimization of cell therapies.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2023
- Employees
- 42
- Website
- cellularintelligence.com/
- Ownership
- Privately Held (backing)
Cellular Intelligence doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellular Intelligence shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellular Intelligence in its N-PORT filings yet. We sweep new filings monthly.